Archives of Medical Research
Volume 41, Issue 3 , Pages 170-181 , April 2010

Actin Cytoskeleton Participation in the Onset of IL-1β Induction of an Invasive Mesenchymal-like Phenotype in Epithelial MCF-7 Cells

  • Janusz Franco-Barraza

      Affiliations

    • Departamento de Biomedicina Molecular, CINVESTAV-IPN, México, D.F. Mexico
    • ,
  • Julio E. Valdivia-Silva

      Affiliations

    • Departamento de Inmunología, Instituto de Investigaciones Biomédicas, UNAM, México, D.F. Mexico
    • ,
  • Horacio Zamudio-Meza

      Affiliations

    • Departamento de Biomedicina Molecular, CINVESTAV-IPN, México, D.F. Mexico
    • ,
  • Aida Castillo

      Affiliations

    • Departmento de Fisiología, CINVESTAV-IPN, México, D.F. Mexico
    • ,
  • Eduardo A. García-Zepeda

      Affiliations

    • Departamento de Inmunología, Instituto de Investigaciones Biomédicas, UNAM, México, D.F. Mexico
    • ,
  • Luis Benítez-Bribiesca

      Affiliations

    • Unidad de Investigación Médica de Enfermedades Oncológicas, CMN-SXXI IMSS, México, D.F. Mexico
    • ,
  • Isaura Meza

      Affiliations

    • Departamento de Biomedicina Molecular, CINVESTAV-IPN, México, D.F. Mexico
    • Corresponding Author InformationAddress reprint requests to: Dr. Isaura Meza, Departamento de Biomedicina Molecular, CINVESTAV-IPN, Apartado 14-740, México, DF 07360, México; Phone: +52 (55) 5747-5000; FAX: +52 (55) 5747-3938

Received 30 January 2010 ,Accepted 6 May 2010.

References 

  1. Yip CH, Anderson BO. The Breast Health Global Initiative: clinical practice guidelines for management of breast cancer in low- and middle-income countries. Expert Rev Anticancer. 2007;7:1095–1104
  2. Lu X, Kang Y. Organotropism of breast cancer metastasis. J Mammary Gland Biol Neoplasia. 2007;12:153–162
  3. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211–217
  4. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867
  5. Aggarwal BB, Shishodia S, Sandur SK, et al. Inflammation and cancer: how hot is the link?. Biochem Pharmacol. 2006;72:1605–1621
  6. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454:436–444
  7. Germano G, Allavena P, Mantovani A. Cytokines as a key component of cancer-related inflammation. Cytokine. 2008;43:374–379
  8. Duque J, Díaz-Muñoz MD, Fresno M, et al. Up-regulation of cyclooxygenase-2 by interleukin-1beta in colon carcinoma cells. Cell Signal. 2006;18:1262–1269
  9. Lianxu C, Hongti J, Changlong Y. NF-kappaBp65-specific siRNA inhibits expression of genes of COX-2, NOS-2 and MMP-9 in rat IL-1beta-induced and TNF-alpha-induced chondrocytes. Osteoarthritis Cartilage. 2006;14:367–376
  10. Tliba O, Tliba S, Da Huang C, et al. Tumor necrosis factor alpha modulates airway smooth muscle function via the autocrine action of interferon beta. J Biol Chem. 2003;278:50615–50623
  11. Paludan SR. Synergistic action of pro-inflammatory agents: cellular and molecular aspects. J Leukoc Biol. 2000;67:18–25
  12. Guarino M. Epithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell Biol. 2007;39:2153–2160
  13. Baum B, Settleman J, Quinlan MP. Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol. 2008;19:294–308
  14. Apte RN, Dotan S, Elkabets M, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006;25:387–408
  15. Krelin Y, Voronov E, Dotan S, et al. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res. 2007;67:1062–1071
  16. Sims JE, Gayle MA, Slack JL, et al. Interleukin 1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci USA. 1993;90:6155–6159
  17. Li X, Qin J. Modulation of Toll-interleukin 1 receptor mediated signaling. J Mol Med. 2005;83:258–266
  18. Sizemore N, Leung S, Stark GR. Activation of phosphatidylinositol 3-se in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol Cell Biol. 1999;19:4798–4805
  19. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28:15–33
  20. Raftopoulou M, Hall A. Cell migration: Rho GTPases lead the way. Dev Biol. 2004;265:23–32
  21. Small JV, Resch GP. The comings and goings of actin: coupling protrusion and retraction in cell motility. Curr Opin Cell Biol. 2005;17:517–523
  22. Singh R, Wang B, Shirvaikar A, et al. The IL-1 receptor and Rho directly associate to drive cell activation in inflammation. J Clin Invest. 1999;103:1561–1570
  23. Vicente-Manzanares M, Koach MA, Whitmore L, et al. Segregation and activation of myosin IIB creates a rear in migrating cells. J Cell Biol. 2008;183:548–554
  24. Mertz KD, Weisheit G, Schilling K, et al. Electroporation of primary neural cultures: a simple method for directed gene transfer in vitro. Histochem Cell Biol. 2002;118:501–506
  25. Benard V, Bohl BP, Bokoch . Characterization of rac and cdc42 activation in chemoattractant-stimulated human neutrophils using a novel assay for active GTPases. J Biol Chem. 1999;274:13198–13204
  26. Valdivia-Silva JE, Franco-Barraza J, Esparza Silva AL, et al. Effect of pro-inflammatory cytokine stimulation on human breast cancer: implications of chemokine receptor expression in cancer metastasis. Cancer Lett. 2009;283:176–185
  27. Cortes-Reynosa P, Robledo T, Macias-Silva M, et al. Src kinase regulates metalloproteinase-9 secretion induced by type IV collagen in MCF-7 human breast cancer cells. Matrix Biol. 2008;27:220–231
  28. Pollard TD, Blanchoin L, Mullins RD. Molecular mechanisms controlling actin filament dynamics in nonmuscle cells. Annu Rev Biophys Biomol Struct. 2000;29:545–576
  29. Chabra ES, Higgs HN. The many faces of actin: matching assembly factor with cellular structures. Nat Cell Biol. 2007;9:1110–1121
  30. Jiang P, Enomoto A, Takahashi M. Cell biology of the movement of breast cancer cells: Intracellular signalling and the actin cytoskeleton. Cancer Lett doi:10.1016/j.canlet.2009.02.034
  31. Kotani K, Hara K, Kotani K, et al. Phosphoinositide 3-kinase as an upstream regulator of the small GTP-binding protein Rac in the insulin signaling of membrane ruffling. Biochem Biophys Res Commun. 1995;208:985–990
  32. Welch HC, Coadwell WJ, Stephens LR, et al. Phosphoinositide 3-kinase-dependent activation of Rac. FEBS Lett. 2003;546:93–97
  33. Reddy SA, Huang JH, Liao WS. Phosphatidylinositol 3-kinase in interleukin 1 signaling. Physical interaction with the interleukin 1 receptor and requirement in NFkappaB and AP-1 activation. J Biol Chem. 1997;272:29167–29173
  34. Arcaro A, Wymann MP. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J. 1993;296(Pt2):297–301
  35. Bosco EE, Mulloy JC, Zheng Y. Rac 1 GTPase: a “Rac” of all trades. Cell Mol Life Sci. 2009;66:370–374
  36. Pestonjamasp KN, Forster C, Sun C, et al. Rac 1 links leading edge and uropod events through Rho and myosin activation during chemotaxis. Blood. 2006;108:2814–2820
  37. Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50–56
  38. Duffy MJ, Maguire TM, Hill A, et al. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000;2:252–257
  39. Cortes-Reynosa P, Robledo T, Macias-Silva M, et al. Src kinase regulates metalloproteinase-9 secretion induced by type IV collagen in MCF-7 human breast cancer cells. Arch Med Res. 2008;27:220–231
  40. Boye K, Maelandsmo GM. S100A4 and metastasis: a small actor playing many roles. Am J Pathol. 2010;176:528–535
  41. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095–2147
  42. Nazarenko I, Marhaba R, Reich E, et al. Tumorigenicity of IL-1α and IL-1β-deficient fibrosarcoma cells. Neoplasia. 2008;10:549–562
  43. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial–mesenchymal transitions. Nature Rev Mol Cell Biol. 2006;7:131–142
  44. Fuchs IB, Lichtenegger W, Buehler H, et al. The prognostic significance of epithelial-mesenchymal transition in breast cancer. Anticancer Res. 2002;22:3415–3419
  45. Hugo H, Ackland ML, Blick T, et al. Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol. 2007;213:374–383
  46. Funakoshi M, Sonoda Y, Tago K, et al. Differential involvement of p38 mitogen-activated protein kinase and phosphatidyl inositol 3-kinase in the IL-1-mediated NF-kappa B and AP-1 activation. Int Immunopharmacol. 2001;1:595–604
  47. Olson MF, Sahai E. The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis. 2009;26:273–287
  48. Kelley LC, Shahab S, Weed SA. Actin cytoskeletal mediators of motility and invasion amplified and overexpressed in head and neck cancer. J Mammary Gland Biol Neoplasia. 2008;2:153–162
  49. Stetler-Stevenson WG, Yu AE. Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol. 2010;11:143–152
  50. Benítez-Bribiesca L, Martínez G, Ruíz MT, et al. Proteinase activity in invasive cancer of the breast. Correlation with tumor progression. Arch Med Res. 1995;26:S163–S168
  51. Harbeck N, Kates RE, Gauger K, et al. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost. 2004;91:450–456
  52. Somiari SB, Somiari RI, Heckman CM, et al. Circulating MMP2 and MMP9 in breast cancer—potential role in classification of patients into low risk, high risk benign disease and breast cancer categories. Int J Cancer. 2006;119:1403–1411
  53. Apte RN, Dotan S, Elkabets M, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006;25:387–408
  54. Radisky DC, Levy DD, Littlepage LE, et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature. 2005;436:123–127
  55. Wang S, Hung M. Cytoplasmic/nuclear shuttling and tumor progression. Ann NY Acad Sci. 2005;1059:11–15

PII: S0188-4409(10)00101-3

doi: 10.1016/j.arcmed.2010.04.010

Archives of Medical Research
Volume 41, Issue 3 , Pages 170-181 , April 2010

Article Tools

* Image Usage & Resolution